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Objectives: To reveal the prevalence and epidemiology of extended-spectrum
β-lactamase (ESBL)- and/or plasmid AmpC (pAmpC)- and carbapenemase (CP)
producing Enterobacteriaceae and vancomycin-resistant enterococci (VRE) across the
Northern Dutch–German border region.
Methods: A point-prevalence study on ESBL/pAmpC/CP producing
Enterobacteriaceae and VRE was carried out in hospitalized patients in the Northern
Netherlands (n = 445, 2012–2013) and Germany (n = 242, 2012). Healthy individuals
from the Dutch community (n = 400, 2010–2012) were also screened. In addition,
a genome-wide gene-by-gene approach was applied to study the epidemiology of
ESBL-Escherichia coli and VRE.
Results: A total of 34 isolates from 27 patients (6.1%) admitted to Dutch hospitals
were ESBL/pAmpC positive and 29 ESBL-E. coli, three pAmpC-E. coli, one
ESBL-Enterobacter cloacae, and one pAmpC-Proteus mirabilis were found. In the
German hospital, 18 isolates (16 E. coli and 2 Klebsiella pneumoniae) from 17 patients
(7.7%) were ESBL positive. In isolates from the hospitalized patients CTX-M-15 was the
most frequently detected ESBL-gene. In the Dutch community, 11 individuals (2.75%)
were ESBL/pAmpC positive: 10 ESBL-E. coli (CTX-M-1 being the most prevalent gene)
and one pAmpC E. coli. Six Dutch (1.3%) and four German (3.9%) hospitalized patients
were colonized with VRE. Genetic relatedness by core genome multi-locus sequence
typing (cgMLST) was found between two ESBL-E. coli isolates from Dutch and German
cross-border hospitals and between VRE isolates from different hospitals within the
same region.
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Conclusion: The prevalence of ESBL/pAmpC-Enterobacteriaceae was similar in
hospitalized patients across the Dutch–German border region, whereas VRE prevalence
was slightly higher on the German side. The overall prevalence of the studied pathogens
was lower in the community than in hospitals in the Northern Netherlands. Cross-
border transmission of ESBL-E. coli and VRE seems unlikely based on cgMLST analysis,
however continuous monitoring is necessary to control their spread and stay informed
about their epidemiology.
Keywords: WGS, cgMLST, VRE, ESBL, hospital, community, prevalence, cross-border research
INTRODUCTION
International travel and patient care are risk factors for
dissemination of bacteria including multidrug-resistant
microorganisms (MDRO), such as extended-spectrum
β-lactamase (ESBL) and carbapenemase (CP)-producing
Enterobacteriaceae (Woerther et al., 2013; Muller et al.,
2015), and vancomycin-resistant enterococci (VRE). The
prevalence of the latter has increased in the last years due to
successful polyclonal subpopulations of hospital-associated (HA)
Enterococcus faecium [previously designated clonal complex
(CC) CC17] and which are also associated with amoxicillin
resistance (ARE) (Arias and Murray, 2012). These populations
are distinct from E. faecium isolates in the community and
isolates from non-human sources (Galloway-Pena et al., 2012;
Lebreton et al., 2013).
Netherlands and Germany as bordering countries with
possible transfer of patients between them, created a
cooperative network to prevent the spread of MDRO and
to harmonize guidelines in healthcare settings1 (Muller
et al., 2015). Surveillance studies to monitor the prevalence,
resistance patterns, and molecular background of MDRO
in hospitals and the community are essential to get insights
into their epidemiology to implement infection prevention
measures. Bacterial whole-genome sequencing (WGS) has
been demonstrated to be very useful for epidemiological
surveillance and detection of antimicrobial resistance (Kwong
et al., 2015). The gene-by-gene approach uses a defined set
of genes to extract an allele-based profile which makes it
scalable and portable between laboratories (Maiden et al., 2013;
Leopold et al., 2014). A core genome multi-locus sequence
typing (cgMLST) scheme has been developed for E. faecium
to distinguish between epidemiologically related and unrelated
isolates (de Been et al., 2015). Although there is no cgMLST
scheme nor threshold publicly approved yet for Escherichia coli,
there are several tools available that allow to define an ad hoc
cgMLST.
The aim of this study was to perform a point-prevalence study
on ESBL/plasmid-mediated AmpC (pAmpC)/CP-producing
Enterobacteriaceae and HA E. faecium (VRE and ARE) in
hospitals in the Northern Dutch–German border region and
to determine the predominant resistance genes. In addition,
stool community samples from the Northern Netherlands were
screened for the same resistant pathogens. A cgMLST was used
1https://www.Deutschland-Nederland.Eu




A prospective point prevalence study was conducted in four
of the largest hospitals (in total 3550 beds) in the Northern
Netherlands between November 2012 and February 2013,
covering a total population of approximately 2.85 million people.
The Hospital Ethical Committee of the University Medical
Center Groningen (UMCG) was informed and patients were
approached to voluntarily participate in the study. Patients
included in this study provided their written informed consent
and a questionnaire concerning epidemiological and clinical
data. The following high-risk wards for antibiotic-resistant
microorganisms were selected: intensive care units (ICU),
vascular surgery, internal medicine hematology/oncology, and
dialysis wards (both for in- and outpatients). Gynecology and
neurology (low-risk wards) were also included for comparison.
From the largest German university hospital in the same
(border) region, patients from four ICUs, a surgical ward, and
a hematology/oncology ward were screened during October
and November 2012 and included in the study. After consent
agreement, all admitted patients from the studied wards were
screened until completing a minimum of 100 samples per
hospital.
The study in healthy people living in the Northern
Netherlands was conducted retrospectively, using control
patients included in a previous case–control study on
microorganisms causing gastroenteritis. Control subjects
were patients attending their general practitioner for a variety
of medical questions, but no gastrointestinal problems, in the
period between August 2010 and December 2012 (Bruijnesteijn
van Coppenraet et al., 2015). No prevalence study was performed
in the community in Germany.
Sample Collection
A total of 445 rectal swabs (Copan ESwabTM) were taken from
hospitalized patients (median age = 66 years, range 18–99 years)
in the Northern Netherlands, 51.7% (n = 230) from men and
48.3% (n = 215) from women. A total of 328 (73.7%) patients
were screened at high-risk wards and 117 (26.3%) patients were
screened at low-risk wards (Table 1). In the German university
hospital, 242 patients (median age= 64 years, range 0–94 years)
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were included, 64.5% (n= 156) men and 35.5% (n= 86) women.
Of these 242 patients, 140 were screened only for ESBL, 22 only
for VRE, and 80 for both. From the Dutch community study, 400
frozen faeces samples were included; 41% (n = 164) from men
and 59% (n = 236) from women, 12% of the samples were from




Dutch Hospitals and Retrospective Dutch Community
Study
Rectal swabs (Dutch hospitalized patients) and approximately
50 µg of feces per sample (Dutch community patients)
were enriched in selective broths: VRA broth containing BHI
(brain heart infusion) with 20 mg/L amphoterin-B, 20 mg/L
aztreonam, 20 mg/L colistin, and 16 mg/L amoxicillin and
TSB-VC broth containing tryptic soy broth with 8 mg/L
vancomycin and 0.25 mg/L cefotaxime. Both broths were
incubated for 24 h at 35 ± 1◦C. Subsequently, 10 µL
of VRA broth was subcultured on VRE Brilliance agar
(Oxoid R©) and BMEG-2 agar (blood agar containing 64 mg/L
meropenem, 2 mg/L gentamicin, 10 mg/L oxacillin, and
20 mg/L amphotericin-B) for identification of VRE and all ARE,
respectively. Ten microliters of TSB-VC broth was subcultured
onto ME/CF/CX comparted plates, containing iso-sensitest agar
with 1 mg/L meropenem, 1 mg/L ceftazidime, or 1 mg/L
cefotaxime, respectively, plus 20 mg/L vancomycin and 20 mg/L
amphotericin-B (Mediaproducts, Groningen), for selection of
ESBL/pAmpC/CP-producing bacteria. Plates were incubated for
24 h at 35 ± 1◦C, except for VRE Brilliance agar plates that were
incubated for 48 h.
Suspected colonies on VRE Brilliance, BMEG-2 and
ME/CF/CX agar plates were streaked on blood agar
(one isolate per morphotype). Species identification was
done by matrix-assisted laser desorption/ionization-time
of flight mass spectrometry (MALDI-TOF MS) (Bruker
Daltonik GmbH, Bremen). Confirmed Enterococcus spp. and
Enterobacteriaceae spp., were tested for antibiotic susceptibility
using VITEK R©2 (bioMérieux) automatic system and EUCAST
clinical breakpoints.
German Hospital
Rectal swabs were directly plated on chromID R© ESBL agar
(bioMérieux) for ESBL screening and enriched EnterococcoselTM
Broth (Bile Esculin Azide Broth) (BD; Becton, Dickinson and
Company) was used for VRE screening and subsequently
cultured on chromID R© VRE agar (bioMérieux).
Species identification and antibiotic susceptibility testing was
done by MALDI-TOF MS (Bruker Daltonik GmbH, Bremen) and
VITEK R©2 (bioMérieux), respectively, following EUCAST criteria.
Confirmation of ESBL was performed using disk diffusion
(cefotaxime 30 µg, cefotaxime 30 µg plus clavulanic acid 10 µg,
ceftazidime 30 µg, ceftazidime plus clavulanic acid 10 µg,
cefepime 30 µg, cefepime 30 µg plus clavulanic acid 10 µg, and
cefoxitin 30 µg) (Mast Diagnostics, Bootle, UK).
PCRs and Microarray
Enterococci isolates from Netherlands were screened by in-house
PCR for IS16 (a marker for specific hospital-associated strains),
vanA and vanB genes as described previously (Clark et al.,
1993; Werner et al., 2011). The GenoType Enterococcus (Hain
Lifescience GmbH) was used in enterococci isolates from
Germany, which detects species and genotypes vanA, vanB,
vanC1, and vanC2. ESBL and VRE positive isolates were sent to
our hospital for further characterization.
Enterobacteriaceae isolates resistant to third generation
cephalosporins and natural chromosomal AmpC producers
intermediate or resistant to cefepime were selected for DNA
extraction using the UltraClean Microbial DNA Isolation Kit (Mo
Bio Laboratories, Inc.) and further characterized for the presence
of ESBL/AmpC genes using a DNA-array (Check-MDR CT103,
Check-points, Wageningen, Netherlands) (Garcia-Cobos et al.,
2015).
Whole-Genome Sequencing of VRE and
ESBL-E. coli
WGS was performed for all ESBL-E. coli and VRE isolates.
For each isolate, several colonies (about 5 µL) of the culture
were suspended in 300 µL microbead solution, which was
subjected to DNA extraction with the Ultraclean Microbial DNA
isolation kit (Mo Bio Laboratories, Carlsbad, CA, United States).
The DNA concentration and purity were measured using a








High-risk (n = 328) 19 (5.8%) 99 (30.2%) 6 (1.8%)
− Intensive care unit (n = 102) 6 (5.9%) 31 (30.4%) 1 (1%)
− Vascular surgery (n = 54) 6 (11.1%) 15 (27.8%) 1 (1%)
− Internal medicine hematology/oncology (n = 81) 1 (1.2%) 36 (44.4%) 2 (2.5%)
− Dialysis (n = 91) 6 (6.6%) 17 (18.7%) 2 (2.2%)
Low-risk (n = 117) 8 (6.8%) 6 (5.1%) 0 (0%)
− Gynecology (n = 55) 3 (5.5%) 1 (1.8%) 0 (0%)
− Neurology (n = 62) 5 (8.1%) 5 (8.1%) 0 (0%)
Total (n = 445) 27 (6.1%) 105 (23.6%) 6 (1.3%)
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NanoDrop 2000c spectrophotometer (Thermo Fisher Scientific,
Waltham, MA, United States) and the Qubit double-stranded
DNA (dsDNA) HS and BR assay kits (Life Technologies,
Carlsbad, CA, United States). One nanogram of bacterial DNA
was used for library preparation. The DNA library was prepared
using the Nextera XT library preparation kit with the Nextera
XT v2 index kit (Illumina, San Diego, CA, United States). The
library fragment length was aimed at fragments with a median
size of 575 bases and was assessed with the Genomic DNA
ScreenTape assay with the 2200 TapeStation system (Agilent
Technologies, Waldbronn, Germany). Subsequently, the library
was sequenced on a MiSeq sequencer, using the MiSeq reagent
kit v2 generating 250-bp paired-end reads. Sequencing was aimed
at a coverage of at least 60-fold. MiSeq data were processed
with MiSeq control software v2.4.0.4 and MiSeq Reporter v2.4
(Illumina, San Diego, CA, United States). Reads were quality-
trimmed using the CLC Genomics Workbench software version
9.0.1 (CLC bio, Aarhus, Denmark) using default settings except
for the following modifications: “trim using quality scores was
set to 0.02” and “discard reads below length was set to 15.”
Subsequently, trimmed-reads were de novo assembled with an
optimal word size of 29 and a minimum contig length of
500. Metrics on raw read and assembly level are provided in
Supplementary Table S1.
cgMLST of VRE and ESBL-E. coli
A genome-wide gene-by-gene comparison approach was used to
determine the genetic relatedness using SeqSphere+ version 3.4.0
(Ridom GmbH, Münster, Germany) (Leopold et al., 2014).
Genome assemblies from the VRE isolates were analyzed using
the E. faecium cgMLST scheme previously published, considering
a cluster alert distance of 20 different alleles (de Been et al., 2015).
An ad hoc cgMLST and whole-genome MLST (wgMLST)
scheme was determined for E. coli isolates using the MLST+
target definer function with default parameters2 and E. coli K-12
as a reference (GenBank accession no. NC_010473.1). The filters
applied to reference genome were: “minimum length filter” that
discards genes shorter than 50 bases; “start codon filter” that
discards all genes that contain no start codon at the beginning
of the gene: “stop codon filter” that discards all genes that contain
no stop codon, more than one stop codon or if the stop codon
is not at the end of the gene: “homologous gene filter” that
discards all genes that have fragments that occur in multiple
copies in a genome (with identity ≥90% and more than 100
bases overlap); “gene overlap filter” that discards the shorter of
two overlapping flanking genes if these genes overlap >4 bp.
The remaining genes were then used in a pairwise comparison
using BLAST (Leopold et al., 2014) with 45 query genomes
(Supplementary Table S2a). All genes of the reference genome
that were common in all query genomes with a sequence identity
of ≥90 and 100 overlap, and with the default parameter stop
codon percentage filter turned on, formed the final cgMLST
scheme; this discards all genes that have internal stop codons in
>20% of the query genomes. Additionally, 26 plasmid sequences
2http://www.ridom.de/seqsphere/ug/v20/Tutorial_for_MLST+_Target_Definer.
html
(Supplementary Table S2b) were added to exclude such genes
are part of the cgMLST typing scheme. The final cgMLST scheme
consisted of 1.771 targets/genes, and 2329 accessory genes were
additionally included for the wgMLST scheme (Supplementary
Tables S3, S4). The minimum coverage of the genome assemblies
was 20 times (Supplementary Table S1) and the percentage of
good targets/genes included in the cgMLST were 97.6% for E. coli
and 98.6% for E. faecium (Supplementary Tables S5, S6).
Furthermore, to determine the genetic relatedness, the genetic
distance for the E. coli isolates was calculated as the proportion
of allele differences: dividing the number of allele differences
between two genomes by the total number of genes commonly
shared by those two genomes (Kluytmans-van den Bergh et al.,
2016). In this study, thresholds for genetic distance were
described to discriminate between epidemiologically related and
unrelated E. coli isolates as 0.0095 when using wgMLST and
0.0105 for cgMLST.
Escherichia coli STs were determined uploading genome
assemblies to SeqSphere+ software following the scheme of
Wirth et al. (2006). Sequence genomes with no conclusive results
for the 7-gene MLST were uploaded to the Enterobase database3.
Additionally, E. colimajor phylogenetic groups (A, B1, B2, and D)
were analyzed in silico by using MLST+ Target Definer function
of SeqSphere+, including the chuA, yjaA, and TSPE4.C2 loci
(Clermont et al., 2000).
Genome assemblies were also uploaded to the Center for
Genomic Epidemiology to extract information on resistance
genes (ResFinder) and virulence factors (VirulenceFinder), and
species confirmation for VRE and ESBL-E. coli (KmerFinder),
and serotype (SerotypeFinder) and plasmid replicons
(PlasmidFinder) for ESBL-E. coli (Zankari et al., 2012; Carattoli
et al., 2014; Hasman et al., 2014; Joensen et al., 2014, 2015; Larsen
et al., 2014).
Statistical Analysis
In the Dutch hospital prevalence study, associations between
ESBL and ARE carriage and the following variables were
analyzed: length of hospital stay, antibiotic use, and (low- or
high-risk) ward. Information was gathered by the questionnaires.
Statistical analyses were performed using SPSS for Windows, v.
20.0. Univariate analyses were performed using the Fisher’s exact
or Chi-square methods for categorical variables. The Mann–
Whitney U-test was used as a non-parametric tests in variables
with no normal distribution. Results with a p-value of ≤0.05





Thirty-four isolates from 27 of the 445 included patients admitted
to hospitals in the Northern Netherlands (6.1%) were confirmed
ESBL and/or pAmpC positive. A total of 85.2% (23/27), 14.8%
3https://enterobase.Warwick.Ac.Uk
Frontiers in Microbiology | www.frontiersin.org 4 October 2017 | Volume 8 | Article 1914
fmicb-08-01914 October 4, 2017 Time: 12:53 # 5
Zhou et al. Epidemiology of ESBL and VRE in Hospitals and the Community
(4/27), and 3.7% (1/27) of these patients were positive for ESBL,
pAmpC, and both, respectively. Among the 34 isolates, 32 were
E. coli, of which 29 were ESBL positive and three were pAmpC
producers. Resistance genes detected in the E. coli isolates are
shown in Table 2. CTX-M-15 (n = 8) and CTX-M-14 (n = 8)
were the most prevalent ones. The other two isolates were
an Enterobacter cloacae, containing a CTX-M-1-like gene and
a pAmpC CMY-II producing Proteus mirabilis. At high-risk
wards, 19 patients (5.8%) were found with ESBL/pAmpC isolates
compared to eight patients (6.8%) at low-risk wards (p = 0.68;
NS). No association was found between ESBL/pAmpC carriage
and antibiotic use, length of hospital stay or ward (Table 1).
In the German hospital, a total of 18 isolates from 17 patients
(17/220; 7.7%) were ESBL positive. Sixteen isolates were E. coli
and two were Klebsiella pneumoniae. Of these, 12 E. coli and one
K. pneumoniae isolates were available for molecular testing. Six
out of 12 (50%) E. coli isolates and the K. pneumoniae isolate had
a CTX-M-15 gene (Table 2).
In the retrospective Dutch community study, 11 patients
(11/400; 2.75%) were ESBL/pAmpC positive: 10 ESBL-E. coli
(CTX-M-1 being the most prevalent gene) and one pAmpC
E. coli (Table 2). Overall, no carbapenem resistance was observed
neither in the community nor in the hospitals.
Escherichia coli MLST and Phylogenetic
Groups
Among ESBL/pAmpC-E. coli isolates from Dutch hospitals, the
most prevalent ST was ST131 (CC, ST131; n = 5, 15.6%), all
of them belonging to phylogroup B2 (Table 2). In the Dutch
community isolates, 10 different STs were found, most of them
belonging to CC ST10 (n = 3, 27.3%) and one isolate to ST131
(phylogroup B2). In the German hospital, the most prevalent STs
were ST38 (33.3%) and ST10 (33.3%) (Table 2).
Amoxicillin- and Vancomycin-Resistant
E. faecium (ARE and VRE)
In the Dutch hospitals, 105 patients (105/445; 23.6%) were
colonized with ARE, including six patients (6/445; 1.3%) with
VRE. All ARE were positive for IS16 and all VRE were
vanB positive. Colonization of ARE (and VRE) was associated
with high-risk wards (p < 0.001), prolonged hospitalization
(p< 0.001), and use of antibiotics (p= 0.05), especially penicillins
and fluoroquinolones (p< 0.001) (Table 3).
In the border German university hospital four (4/102; 3.9%)
VRE isolates were isolated. Three of them were vanA positive and
one was vanB positive.
In the retrospective Dutch community study, six ARE (6/400;
1.5%) were found, three of them were IS16 positive. Only one
vanA-VRE (1/400; 0.25%) was found, this strain was amoxicillin
susceptible and IS16 negative.
cgMLST and wgMLST Comparison of
ESBL-E. coli Isolates from the
Community and Hospitals
Genome assemblies of 55 ESBL-E. coli [Dutch community
(n = 11), Dutch hospitals (n = 32), and German hospital
(n = 12)] of this study were analyzed by a gene-by-gene
approach and the allelic distance from the cgMLST and wgMLST
were visualized in a minimum spanning tree (Figure 1 and
Supplementary Figure S1, respectively).
Six groups of isolates with a lower number of different
alleles (≤35) by cgMLST were further analyzed. Supplementary
Table S7 summarizes the origin of the isolates in every group
and the core and whole-genome genetic distance. Those groups
formed by isolates with an epidemiological link (isolated from
the same patient; group 1, 4, 5a, 6a, and 7), showed a core and
whole-genome genetic distance lower than 0.0030 and 0.0046,
respectively. In addition, isolates of group 5b, although with
unknown epidemiological link, had a core genetic distance of
0.0063 and a whole-genome genetic distance of 0.0076. Both
isolates were positive for CTX-M-14, however, no plasmid
replicons were found in one of them (isolate 38_Esco_HA-DE)
(Supplementary Table S7).
Among those groups including isolates with non
(or unknown) epidemiological link, the core genome genetic
distance was between 0.0122 and 0.0199 and the whole-genome
genetic distance was between 0.0104 and 0.0208 (groups 2, 3, 6b,
and 6c; Figure 1). Resistance and virulence profiles of the isolates
are shown in Supplementary Table S8.
cgMLST Comparison of VRE Isolates
from the Community and Hospitals
A minimum spanning tree was created for the 11 VRE isolates
[Dutch community (n= 1), Dutch hospitals (n= 6), and German
hospital (n = 4)]. Two clusters of isolates from different patients
were observed (Figure 2). One cluster of four vanB-VRE isolates
from the Dutch hospital belonged to cluster type (CT) 110 (ST17);
two isolates were from the same ward in hospital A and the other
two isolates were isolated from different wards in hospital B.
The other cluster of two vanA-VRE isolates were isolated from
different wards from the German hospital (CT 20, ST203). The
resistance and virulence genotypes of VRE isolates are shown in
Supplementary Table S8.
Nucleotide Sequence Accession Number
Sequence data obtained in this study has been deposited at the
National Center for Biotechnology Information under BioProject
no. PRJNA352198.
DISCUSSION
This study shows the molecular epidemiology of ESBL/pAmpC-
E. coli and HA E. faecium in hospitals in the Northern
Dutch–German border region and the community in the
Northern Netherlands. Dutch hospitals showed a prevalence
for ESBL/pAmpC – Enterobacteriaceae, VRE, and ARE of 6.1,
1.3, and 23.6%, respectively, whereas the prevalence in the
community was 2.75, 0.25, and 1.5%, respectively. The German
hospital had an ESBL/pAmpC prevalence of 7.7 and 3.9% for
VRE.
A previous study reported a prevalence of ESBL-producing
bacteria of 4.9% in the Netherlands (Overdevest et al., 2014),
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TABLE 2 | Molecular characterization of the E. coli isolates from the community and hospital patients in the Netherlands and Germany.
Sample1 Hospital/ward β-Lactamase genes Phylogroup ST CC
Community
1_Esco_CA-NL blaCTX-M-1, blaTEM-1B B2 131 ST131
2_Esco_CA-NL blaSHV-12 B2 117 None
3_Esco_CA-NL blaCMY-2 D 2309 None
4_Esco_CA-NL blaCTX-M-1 D 57 ST350
5_Esco_CA-NL blaCTX-M-1, blaTEM-1B A 10 ST10
6_Esco_CA-NL blaCTX-M-1, blaTEM-1B B1 1079 None
7_Esco_CA-NL blaCTX-M-1, blaTEM-1B A 10 ST10
8_Esco_CA-NL blaCTX-M-15 D 648 ST648
9_Esco_CA-NL blaCTX-M-15 A 617 ST10
10_Esco_CA-NL blaCTX-M-15 A 1312 None
11_Esco_CA-NL blaCTX-M-14b, blaTEM-1B D 38 ST38
Hospital
12_Esco_HA-NL A/Gynecology blaCTX-M-15, blaTEM-1B D 5463 None
12b_Esco_HA-NL A/Gynecology blaCTX-M-15, blaTEM-1B D 5463 None
13_Esco_HA-NL A/Neurology blaCTX-M-27 B2 131 ST131
14_Esco_HA-NL A/Dialysis outpatient blaCTX-M-15, blaTEM-1B A 93 ST168
15_Esco_HA-NL A/ICU blaCMY-2, blaTEM-1B D 354 ST354
16_Esco_HA-NL A/ICU blaCTX-M-15, blaTEM-1B, blaOXA-1 B1 58 ST155
17_Esco_HA-NL A/ICU blaCTX-M-15, blaTEM-1B B1 38 ST38
18_Esco_HA-NL A/ICU blaTEM-52C B1 453 ST86
19_Esco_HA-NL A/ICU blaCTX-M-1 B1 641 ST86
20_Esco_HA-NL A/ICU blaSHV-12 A 5888 None
20b_Esco_HA-NL A/ICU blaCTX-M-1 B1 58 ST155
21_Esco_HA-NL B/Gynecology blaCTX-M-14 B1 101 ST101
22_Esco_HA-NL B/Dialysis outpatient blaCTX-M-14 B1 38 ST38
22c_Esco_HA-NL B/Dialysis outpatient blaCTX-M-14 D 38 ST38
23_Esco_HA-NL B/Vascular surgery blaCMY-2, blaTEM-1B D 1508 None
24_Esco_HA-NL B/Neurology blaTEM-52C D 2064 None
25_Esco_HA-NL B/Neurology blaCTX-M-3, blaTEM-1B B2 95 ST95
25b_Esco_HA-NL B/Neurology blaCTX-M-3, blaTEM-1B D 95 ST95
26_Esco_HA-NL C/Gynecology blaCTX-M-15, blaOXA-1 B2 131 ST131
27_Esco_HA-NL C/Dialysis outpatient blaCTX-M-1, blaTEM-33 A 3478 None
28_Esco_HA-NL C/Dialysis outpatient blaCTX-M-14 A 10 ST10
29_Esco_HA-NL C/Neurology blaCTX-M-1 B1 603 None
30_Esco_HA-NL C/Vascular surgery blaCTX-M-14 A 410 ST23
31_Esco_HA-NL D/Vascular surgery blaCTX-M-14, blaTEM-1B, blaOXA-1 B1 58 ST155
32_Esco_HA-NL D/Vascular surgery blaCTX-M-1 D 117 None
32b_Esco_HA-NL D/Vascular surgery blaDHA-1, blaTEM-1B B2 131 ST131
33_Esco_HA-NL D/Vascular surgery blaCTX-M-14 D 69 ST69
33b_Esco_HA-NL D/Vascular surgery blaCTX-M-14 D 69 ST69
34_Esco_HA-NL D/Internal medicine blaCTX-M-55, blaOXA-1 B1 4385 None
35_Esco_HA-NL D/Dialysis outpatient blaCTX-M-15, blaTEM-1B, blaOXA-1 B2 131 ST131
35b_Esco_HA-NL D/Dialysis outpatient blaCTX-M-15, blaOXA-1 B2 131 ST13
36_Esco_HA-NL D/Dialysis outpatient blaCTX-M-1, blaTEM-1B B1 58 ST155
37_Esco_HA-DE ICU 1 blaCTX-M-15 D 38 ST38
38_Esco_HA-DE ICU 6 blaCTX-M-14 D 38 ST38
39_Esco_HA-DE ICU 2 blaCTX-M-14 A 10 ST10
40_Esco_HA-DE ICU 6 blaCTX-M-15, blaTEM-1B, blaOXA-1 B1 448 ST448
41_Esco_HA-DE Surgical ward blaCTX-M-1, blaTEM-1B A 10 ST10
42_Esco_HA-DE Hemato-oncology ward blaCTX-M-15, blaTEM-1B, blaOXA-1 A 90 ST23
(Continued)
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TABLE 2 | Continued
Sample1 Hospital/ward β-Lactamase genes Phylogroup ST CC
43_Esco_HA-DE ICU 4 blaCTX-M-15, blaOXA-1 A 34 ST10
44_Esco_HA-DE ICU 3 blaTEM-187 A 10 ST10
45_Esco_HA-DE ICU 3 blaCTX-M-15, blaOXA-1 D 38 ST38
46_Esco_HA-DE ICU 3 blaCTX-M-1, blaTEM-1B A 10 ST10
47_Esco_HA-DE ICU 1 blaCTX-M-15 D 38 ST38
48_Esco_HA-DE ICU 1 blaCTX-M-14, blaTEM-1B D 1177 –
1CA, community acquired; HA, hospital acquired; NL, Netherlands; DE, Germany; numbers refer to individual patients and a letter behind a number indicates that more
than one isolate was obtained from the patient.
comparable to the 6.1% prevalence observed in Dutch hospitals
in this study. A prevalence of 5.6% ESBL-producing E. coli
isolates in hospitalized and ambulatory patients in Germany
has been reported recently (Pietsch et al., 2015), which
is slightly lower than the 7.7% observed in the present
study.
Furthermore, we observed an ESBL-E. coli prevalence of
2.5% in the Northern Netherlands community, which is low
compared to previous studies in other regions, in which the
prevalence in the community ranged from 4.7% (2009) to 10.1%
(2011) (Reuland et al., 2013; van Hoek et al., 2015). This
difference may have several reasons. First, ESBL prevalence may
vary between regions and over time, and natural eradication
of resistant Enterobacteriaceae might occur over time in the
community (Bar-Yoseph et al., 2016). Additionally, samples
included in this study were only chosen from patients without any
gastrointestinal complaints, a factor which otherwise has been
described to be associated with high ESBL prevalence (Reuland
et al., 2013).
The majority of the resistance genes found in our community
isolates were CTX-M-1 which is broadly disseminated among
animals in Europe, especially in cattle and pigs, followed by
the CTX-M-15 gene, commonly associated with human origin
(Reuland et al., 2013; Pietsch et al., 2015). The latter was the most
frequent gene among the Dutch and German hospital isolates, in
concordance with previous studies (Ewers et al., 2012; Reuland
et al., 2013; Pietsch et al., 2015).
The pAmpC prevalence in E. coli in our study was 0.3%,
comparable to the prevalence of 0.6% what was reported in the
study of van Hoek et al. (2015) (0.6% pAmpC Enterobacteriaceae)
and somewhat lower to findings of Reuland et al. (2015)
(1.3% pAmpC-E. coli). The most common pAmpC gene found in
hospital and community isolates were CMY-II, which is together
with DHA frequently found in human isolates (Reuland et al.,
2015).
ESBL-producing E. coli belonging to CC ST131-phylogroup
B2 are usually associated with more virulent strains (Overdevest
et al., 2015). These were frequently found in the Dutch hospitals
included in the present study but only sporadically in the
community samples. This CC ST131-phylogroup B2 was also
prevalent in a study carried out in hospitals in the Rotterdam
region (van der Bij et al., 2011). CC ST10 was predominant
among the ESBL-producing E. coli in the community, the same
CC was also described to be prevalent in another Dutch study in
community patients (Reuland et al., 2013).
We observed an overall ARE and VRE prevalence in
hospitalized patients of 23.6 and 1.3%, respectively. Similar
observations were made in a study performed in Dutch
hospitals in 2008 reporting ARE carriage rates of 10–16%
upon admission and 15–39% on acquisition in hematology
and gastroenterology/nephrology wards (de Regt et al., 2008).
The clinical significance of enterococcal infections and active
VRE screening has been a matter of discussion. However, in
immunocompromised patients, high morbidity and mortality
TABLE 3 | Variables associated with carriage of amoxicillin-resistant E. faecium (ARE) and extended-spectrum β-lactamase (ESBL)- and/or plasmid AmpC (pAmpC)-
producing Enterobacteriaecae.




Hospitalization days median (range) 12 (1− 127) 3 (1− 107) p < 0.001 4 (1− 127) 4 (1− 36) p = 0.886
Ward p < 0.001 p = 0.657
High-risk (n = 328) 99 (94.3%) 229 (67.4%) 19 (70.4%) 309 (73.9%)
Low-risk (n = 117) 6 (5.7%) 111 (32.6%) 8 (29.6%) 109 (26.1%)
Antibiotic use (n = 145) 62 (59%) 83 (24.4%) p < 0.001 7 (25.9%) 138 (33%) p = 0.529
Penicillins∗∗ 26 (24.8%) 29 (8.5%) p < 0.001 3 (11.1%) 35 (8.4%) p = 0.494
Fluoroquinolones 28 (26.7%) 15 (4.4%) p < 0.001 1 (3.7%) 42 (10%) p = 0.499
Third generation cephalosporins 11 (10.5%) 19 (5.6%) p = 0.081 1 (3.7%) 29 (6.9%) p = 1.00
∗Results with a p-value of ≤0.05 were considered to be statistically significant. All p-values are two-tailed. ∗∗Used penicillins: benzylpenicillin, flucloxacillin, amoxicillin–
clavulanic acid, and piperacillin–tazobactam.
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FIGURE 1 | Minimum spanning tree of ESBL-E. coli isolates from hospitals and the community. Distance based on a cgMLST of 1771 genes using the parameters
“pairwise ignoring missing values” during calculation. Each circle represents a genotype, colors indicate geographical origin and community or hospital. Orange:
hospital—Netherlands; blue: hospital—Germany; green: community—Netherlands. Number of different alleles are indicated on the edges between connected
isolates (nodes). The cut-off values for defining a group was 35 alleles. Isolates are presented by their ID and ST.
rates have been reported in infections caused by enterococci
(Zhou et al., 2013). In this study, ARE/VRE carriage was
associated with prolonged hospitalization and antibiotic use,
which is in line with previous literature (Torell et al., 1999). We
found a high carriage rate of ARE in high-risk wards (30.2%).
Notably, these patients may be at risk for a subsequent infection.
Since 2011, VRE started to become a problem in multiple
hospitals in the Netherlands: a total of 14 hospitals were affected
with outbreaks of VRE in October 2012 (van den Brink, 2013).
However, in this study a prevalence of VRE (vanB) carriage of
only 1.3% was found. This is probably due to extensive infection
prevention measures and successful outbreak management
control. The prevalence of 1.3% is similar to what has been
previously published in the Netherlands, with prevalence rates
ranging from 1.4 to 2% in the 1990s (Endtz et al., 1997; van den
Braak et al., 2000). The VRE prevalence in the German hospital
was slightly higher (3.9%), though it is known that Germany has
a higher VRE prevalence compared to the Netherlands4.
In our Dutch community one vanA-VRE was found, that
was amoxicillin susceptible and IS16 negative, indicative for a
non-hospital origin (Galloway-Pena et al., 2012; Lebreton et al.,
4Antimicrobial Resistance Interactive Database (EARS-Net) (http://ecdc.Europa.
eu/en/)
2013). Endtz et al. (1997) reported a higher number of VRE
in the community (2%), however, this study did not include
information about amoxicillin resistance nor IS16 which makes it
difficult to determine if they had a hospital or non-hospital origin
(Galloway-Pena et al., 2012; Lebreton et al., 2013).
The cgMLST analysis in our study showed heterogeneity
among E. coli species, and isolates were genetically distributed
independently of their origin. The hospital and community
ESBL-E. coli isolates included in this study did not show any
genetic relatedness except for the ones isolated from the same
patient and for two isolates (group 5b) from patients in different
hospitals across the Dutch–German border, in a distance of
approximately 200 km and with no known epidemiological link.
The patient from the Dutch hospital was a dialyses outpatient
(isolation date December 2012) whereas the patient from the
German hospital was admitted to ICU (isolation date November
2012). Interestingly, both isolates harbored the same ESBL gene
and virulence factors.
Genetic relatedness was found between four VRE isolates
(CT110) from patients from two different Dutch hospitals
(Figure 2), which indicates transmission between wards, but
also between hospitals in a close geographical region similar
to findings of a previous population-based study of VRE using
WGS that also showed intra- and inter-regional spread of closely
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FIGURE 2 | Minimum spanning tree of VREfcm, cgMLST based on 1423 genes using the parameters “pairwise ignoring missing values” during distance calculation.
Each circle represents a genotype and colors indicate cluster types (CT). Number of different alleles are indicated on the edges between connected isolates (nodes).
Isolates are presented by their ID, ST, and CT.
related VRE isolates (Pinholt et al., 2015). Although no genetic
relatedness was found between VRE isolates of Dutch and
German hospitals, the numbers of VRE isolates were too low
to draw definite conclusions. It is known that several VRE CT
co-circulate in Germany and the Netherlands (data not shown).
However, only some laboratories have implemented the use of
cgMLST in their routine to analyze VRE outbreaks and more
epidemiological studies are needed to investigate cross-border
transmission of VRE.
To our knowledge, there are no similar studies that compare
and investigate the molecular epidemiology of ESBL-E. coli and
VRE in hospitals and the community by WGS. Recently, the same
approach has been used to study the clonality of ESBL-producing
Enterobacteriaceae from environmental and stool samples from
farmers suggesting possible cross-transmission between the
farmers and the environment. This was only based on number of
allele differences (Fischer et al., 2016) which makes it difficult to
interpret results without considering the total number of genes
included in the cgMLST scheme. In our study, we determined
the genetic relatedness between ESBL-E. coli using cgMLST or
wgMLST comparison and genetic distance calculation. These
results were in concordance with the genetic distance thresholds
of 0.0095 (wgMLST) and 0.0105 (cgMLST) previously established
for E. coli based on known existing epidemiological links by
analyzing more than 2000 ESBL-Enterobacteriaceae isolates from
Dutch hospitals (Kluytmans-van den Bergh et al., 2016).
In another study, a cgMLST approach for several MDR
bacteria was prospectively used for taking relevant infection
control decisions in a hospital setting (Mellmann et al., 2016).
A threshold of >10 differing alleles was defined to exclude
nosocomial transmission of MDR E. coli (Mellmann et al., 2016).
If we would have applied this threshold we would have missed
the genetic relatedness between isolates belonging to group 5b,
presenting 11 different alleles (Figure 1 and Supplementary
Table S7). This highlights that thresholds based on number of
allele differences are only applicable to specific collections within
a study, whereas the genetic distance calculation seems to give a
more objective result, independently of the analyzed population.
We acknowledge this study has some limitations. No
community study in the German cross-border region, neither
ARE monitoring in the German hospital were performed.
Laboratory methods for isolation of ESBL Enterobacteriaceae and
VRE differed between Dutch and German hospitals since no
enrichment broth was used in Germany, however, selective media
agar was used in both regions. Since this study was anonymous,
some epidemiological data were not available which makes it
more difficult to draw conclusions regarding genetic relatedness
among isolates between patients.
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CONCLUSION
In conclusion, the results of this study suggest that
ESBL/pAmpC-E. coli circulate in the hospital and the
community, although a higher prevalence of ESBL/pAmpC-
E. coli was observed in hospitals compared to the community
in the Northern Netherlands. Hospitals in the Northern
Dutch–German region showed a similar prevalence of ESBL/
pAmpC-Enterobacteriaceae. VRE prevalence was still low in
the hospital as well as in the community in the Northern
Netherlands. The German hospital showed a slightly higher VRE
prevalence compared to hospitals in the Northern Netherlands.
Nosocomial but no cross-border transmission of VRE was
observed in this study. Epidemiologically related ESBL-E. coli
and VRE were uncommon across the Northern Dutch–German
border in the studied population, as only two ESBL-E. coli isolates
from a Dutch and a German hospital were genetically similar.
Cooperation between bordering countries and continuous
monitoring using high discriminatory typing methods are still
necessary to keep the epidemiology of resistant pathogens
updated thereby helping to control their spread.
These results were partially presented at the ECCMID
conference 2016, Amsterdam.
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TABLE S2a | Finished E. coli query genomes used in this study to develop and
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